|
1
|
Ali AM, Lizhi N, Jialiang L, Fei Y, Yuan
W, Jianying Z, Jin Y, Jibing C, Feng M and Kecheng X:
Cryoprotective therapy for hepatocellular carcinoma: Study of 51
patients with a single lesion. Cryobiology. 69:61–67. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alnaggar M, Niu L, Li J, Yao F, Wang Y,
Zeng J, Ye J, Chen J, Mu F and Xu K: Cryoprotective therapy for
huge hepatocellular carcinoma: A study of 14 patients with a single
lesion. Cryobiology. 69:457–461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pearson AS, Izzo F, Fleming RY, Ellis LM,
Delrio P, Roh MS, Granchi J and Curley SA: Intraoperative
radiofrequency ablation or cryoablation for hepatic malignancies.
Am J Surg. 178:592–599. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chung CD, Lau LL, Ko KL, Wong AC, Wong S,
Chan AC, Poon RT, Lo CM and Fan ST: Laparoscopic liver resection
for hepatocellular carcinoma. Asian J Surg. 33:168–172. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ravikumar TS, Kane R, Cady B, Jenkins R,
Clouse M and Steele G Jr: A 5-year study of cryosurgery in the
treatment of liver tumors. Arch Surg. 126:1520–1524. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sarantou T, Bilchik A and Ramming KP:
Complications of hepatic cryosurgery. Semin Surg Oncol. 14:156–162.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seifert JK and Morris DL: World survey on
the complications of hepatic and prostate cryotherapy. World J
Surg. 23:109–114. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shafir M, Shapiro R, Sung M, Warner R,
Sicular A and Klipfel A: Cryoablation of unresectable malignant
liver tumors. Am J Surg. 171:27–31. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schweitzer A, Horn J, Mikolajczyk RT,
Krause G and Ott JJ: Estimations of worldwide prevalence of chronic
hepatitis B virus infection: A systematic review of data published
between 1965 and 2013. Lancet. 386:1546–1555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Al-Sakere B, André F, Bernat C, Connault
E, Opolon P, Davalos RV, Rubinsky B and Mir LM: Tumor ablation with
irreversible electroporation. PloS One. 2:e11352007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edd JF, Horowitz L, Davalos RV, Mir LM and
Rubinsky B: In vivo results of a new focal tissue ablation
technique: Irreversible electroporation. IEEE Trans Biomed Eng.
53:1409–1415. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Charpentier KP, Wolf F, Noble L, Winn B,
Resnick M and Dupuy DE: Irreversible electroporation of the liver
and liver hilum in swine. HPB (Oxford). 13:168–173. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Péus D, Newcomb N and Hofer S: Appraisal
of the karnofsky performance status and proposal of a simple
algorithmic system for its evaluation. BMC Med Inform Decis Mak.
13:722013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cholongitas E, Papatheodoridis GV, Vangeli
M, Terreni N, Patch D and Burroughs AK: Systematic review: The
model for end-stage liver disease-should it replace Child-Pugh's
classification for assessing prognosis in cirrhosis? Aliment
Pharmacol Ther. 22:1079–1089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu HM, Chen Y, Xu J and Zhou Q:
Drug-induced liver injury in hospitalized patients with notably
elevated alanine aminotransferase. World J Gastroenterol.
18:5972–5978. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kos B, Voigt P, Miklavcic D and Moche M:
Careful treatment planning enables safe ablation of liver tumors
adjacent to major blood vessels by percutaneous irreversible
electroporation (IRE). Radiol Oncol. 49:234–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dollinger M, Muller-Wille R, Zeman F,
Haimerl M, Niessen C, Beyer LP, Lang SA, Teufel A, Stroszczynski C
and Wiggermann P: Irreversible electroporation of malignant hepatic
tumors-alterations in venous structures at subacute follow-up and
evolution at mid-term follow-up. PloS One. 10:e01357732015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dollinger M, Zeman F, Niessen C, Lang SA,
Beyer LP, Müller M, Stroszczynski C and Wiggermann P: Bile duct
injury after irreversible electroporation of hepatic malignancies:
Evaluation of MR imaging findings and laboratory values. J Vasc
Interv Radiol. 27:96–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dollinger M, Beyer LP, Haimerl M, Niessen
C, Jung EM, Zeman F, Stroszczynski C and Wiggermann P: Adverse
effects of irreversible electroporation of malignant liver tumors
under CT fluoroscopic guidance: A single-center experience. Diagn
Interv Radiol. 21:471–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scheffer HJ, Nielsen K, de Jong MC, van
Tilborg AA, Vieveen JM, Bouwman AR, Meijer S, van Kuijk C, van den
Tol PM and Meijerink MR: Irreversible electroporation for
nonthermal tumor ablation in the clinical setting: A systematic
review of safety and efficacy. J Vasc Interv Radiol. 25:997–1011;
quiz 1011. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cohen EI, Field D, Lynskey GE and Kim AY:
Technology of irreversible electroporation and review of its
clinical data on liver cancers. Expert Rev Med Devices. 15:99–106.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ryan MJ, Willatt J, Majdalany BS, Kielar
AZ, Chong S, Ruma JA and Pandya A: Ablation techniques for primary
and metastatic liver tumors. World J Hepatol. 8:191–199. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Ren Z, Zhu T, Zhang X, Peng Z, Xie
H, Zhou L, Yin S, Sun J and Zheng S: Electric ablation with
irreversible electroporation (IRE) in vital hepatic structures and
follow-up investigation. Sci Rep. 5:162332015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Min JH, Waters P, Vincent A, Lee S, Shin Y
H, Lee H K and Kim BJ: Reduced serum uric acid levels in
neuromyelitis optica: Serum uric acid levels are reduced during
relapses in NMO. Acta Neurol Scand. 126:287–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lord J, Willis S, Eatock J, Tappenden P,
Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A,
Taylor S, et al: Economic modelling of diagnostic and treatment
pathways in National Institute for Health and Care Excellence
clinical guidelines: The modelling algorithm pathways in guidelines
(MAPGuide) project. Health Technol Assess. 17(v-vi): 1–192.
2013.
|
|
26
|
Wichtowski M, Nowaczyk P, Kocur J and
Murawa D: Irreversible electroporation in the treatment of locally
advanced pancreas and liver metastases of colorectal carcinoma.
Contemp Oncol (Pozn). 20:39–44. 2016.PubMed/NCBI
|
|
27
|
Froud T, Venkat SR, Barbery KJ, Gunjan A
and Narayanan G: Liver function tests following irreversible
electroporation of liver tumors: Experience in 174 procedures.
Techn Vasc Interv Radiol. 18:140–146. 2015. View Article : Google Scholar
|
|
28
|
Silk MT, Wimmer T, Lee KS,
Srimathveeravalli G, Brown KT, Kingham PT, Fong Y, Durack JC,
Sofocleous CT and Solomon SB: Percutaneous ablation of peribiliary
tumors with irreversible electroporation. J Vasc Interv Radiol.
25:112–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kingham TP, Karkar AM, D'Angelica MI,
Allen PJ, Dematteo RP, Getrajdman GI, Sofocleous CT, Solomon SB,
Jarnagin WR and Fong Y: Ablation of perivascular hepatic malignant
tumors with irreversible electroporation. J Am Coll Surg.
215:379–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thomson KR, Cheung W, Ellis SJ, Federman
D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C and
Haydon A: Investigation of the safety of irreversible
electroporation in humans. J Vasc Interv Radiol. 22:611–621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sugimoto K, Moriyasu F, Kobayashi Y, Saito
K, Takeuchi H, Ogawa S, Ando M, Sano T, Mori T, Furuichi Y and
Nakamura I: Irreversible electroporation for nonthermal tumor
ablation in patients with hepatocellular carcinoma: Initial
clinical experience in Japan. Jpn J Radiol. 33:424–432. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cannon R, Ellis S, Hayes D, Narayanan G
and Martin RC II: Safety and early efficacy of irreversible
electroporation for hepatic tumors in proximity to vital
structures. J Surg Oncol. 107:544–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hosein PJ, Echenique A, Loaiza-Bonilla A,
Froud T, Barbery K, Lima Rocha CM, Yrizarry JM and Narayanan G:
Percutaneous irreversible electroporation for the treatment of
colorectal cancer liver metastases with a proposal for a new
response evaluation system. J Vasc Interv Radiol. 25(1233–1239):
e22014.
|
|
34
|
Distelmaier M, Barabasch A, Heil P,
Kraemer NA, Isfort P, Keil S, Kuhl CK and Bruners P: Midterm safety
and efficacy of irreversible electroporation of malignant liver
tumors located close to major portal or hepatic veins. Radiology.
285:1023–1031. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Q and Teng G: Interventional therapy
of colorectal liver metastasis. Zhonghua Wei Chang Wai Ke Za Zhi.
20:621–624. 2017.(In Chinese). PubMed/NCBI
|
|
36
|
Lyu T, Wang X, Su Z, Shangguan J, Sun C,
Figini M, Wang J, Yaghmai V, Larson AC and Zhang Z: Irreversible
electroporation in primary and metastatic hepatic malignancies: A
review. Medicine (Baltimore). 96:e63862017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
